Following the announcement by Sanofi and Luminostics to co-develop a smartphone-based self-testing solution for COVID-19;

Aliyah Farouk, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view:

“There are currently no commercial, over-the-counter COVID-19 self-testing solutions available. Therefore, although Sanofi and Luminostics’ test will not be ready until the end of the year, GlobalData expects that demand for widely available rapid diagnostics will drive the success of this product and considerably disrupt the COVID-19 diagnostics market.

“With a surge in personal health monitoring and self-testing platforms, it is no surprise that Sanofi leveraged Luminostics’ proprietary technology to provide a highly sought diagnostic solution. The company is currently at the forefront in the fight against COVID-19 with numerous clinical trials in the pipeline. GlobalData expects this strategic collaboration will cement Sanofi’s position in the lucrative COVID-19 diagnostics market in addition to increasing Luminostics’ visibility.

“As the virus spreads, rapid testing and safe containment continue to be a challenge. The development of commercial tests will enable individuals to remain in self-isolation, preventing large numbers of resource intensive hospital admissions as well as overcoming supply chain challenges.”